MISSING SCRIPT / EVIDENCE EXPLORER
Evidence Summary Engine
Find integrative-care research by cancer diagnosis, clinical goal and treatment context. Evidence is linked to published records, not generated as individualized medical advice.
Discuss every result with your oncology team
Important: This educational navigator is not a treatment recommendation, clinical decision tool or complete interaction checker. Diagnosis, stage, treatment and other medicines can change safety and eligibility. Discuss any integrative intervention and supplement with your oncologist and oncology pharmacist before use. Never delay proven treatment. If you have a new severe symptom, contact your care team promptly.
Choose your diagnosis
Breast cancer · Colorectal cancer · Prostate cancer · Head and neck cancer · Pancreatic cancer
Current interface: Choose a cancer below. The summaries are curated links to evidence records; the site does not currently collect treatment details or automatically calculate individual interactions.
Breast cancer
Hormonal therapy, chemotherapy and survivorship
Evidence categories: Supportive care · disease control · safety. The labels below are descriptive; they are not formal GRADE assessments.
Acupuncture for aromatase-inhibitor joint pain
Randomized clinical benefit for joint pain; not an anticancer treatment. Read the evidence record →
Soy foods after breast cancer
Food and concentrated isoflavone supplements are not interchangeable. Read the evidence record →
Black cohosh for hot flashes
Negative randomized efficacy findings; liver and product-quality concerns. Read the evidence record →
Exercise during neoadjuvant therapy
Primary tumor-response finding was negative. Read the evidence record →
Safety and drug-interaction review: Ask about endocrine therapy, chemotherapy, liver disease, anticoagulants and the actual supplement formulation. Food findings do not validate concentrated botanical extracts.
Clinical trials
- NCT06534125 — Acupuncture or acupressure to prevent aromatase-inhibitor joint pain. Early-stage hormone receptor-positive breast cancer; women matching the trial’s specified eligibility. Registry status: recruiting; last update January 29, 2026.
Search additional trials: Search ClinicalTrials.gov for Breast cancer studies recruiting or not yet recruiting →. Results update at the registry; verify condition, intervention, eligibility and status on each study. Search links are not a vetted list of matching trials.
Colorectal cancer
Adjuvant care, metastatic care and treatment side effects
Evidence categories: Supportive care · disease control · safety. The labels below are descriptive; they are not formal GRADE assessments.
High-dose vitamin D in metastatic disease
Phase III did not demonstrate progression-free or overall survival benefit. Read the evidence record →
St. John’s wort and irinotecan
Documented reduction in irinotecan exposure; potentially consequential interaction. Read the evidence record →
Pomegranate products and cancer progression — different disease
Do not extrapolate findings from prostate to colorectal cancer. Read the evidence record →
Safety and drug-interaction review: Patients on irinotecan should avoid self-prescribing St. John’s wort. Discuss all oral extracts and vitamin regimens with the oncology pharmacist.
Clinical trials
- NCT06502275 — Exercise and nutrition–based frailty prevention. Older adults with colorectal cancer; mobile-health intervention. Registry status: recruiting; last update September 18, 2025. Estimated completion date has passed, so confirm enrollment with the study team.
Search additional trials: Search ClinicalTrials.gov for Colorectal cancer studies recruiting or not yet recruiting →. Results update at the registry; verify condition, intervention, eligibility and status on each study. Search links are not a vetted list of matching trials.
Prostate cancer
Active surveillance, androgen deprivation and metastatic disease
Evidence categories: Supportive care · disease control · safety. The labels below are descriptive; they are not formal GRADE assessments.
High-vegetable diet on active surveillance
Randomized cancer-progression trial was negative. Read the evidence record →
Pomegranate products and PSA kinetics
PSA-marker findings did not establish clinical progression benefit. Read the evidence record →
Exercise with bone metastases
Supports lesion-aware functional rehabilitation; not tumor control. Read the evidence record →
Safety and drug-interaction review: Bone metastases require individualized exercise safety assessment; PSA changes are not proof of extended survival.
Clinical trials
- NCT05751434 — Exercise therapy and prostate-cancer-related outcomes. City of Hope exercise study. Registry status: recruiting; last update July 30, 2026.
Search additional trials: Search ClinicalTrials.gov for Prostate cancer studies recruiting or not yet recruiting →. Results update at the registry; verify condition, intervention, eligibility and status on each study. Search links are not a vetted list of matching trials.
Head and neck cancer
Radiotherapy-associated toxicity and rehabilitation
Evidence categories: Supportive care · disease control · safety. The labels below are descriptive; they are not formal GRADE assessments.
Photobiomodulation for oral mucositis
Supportive-care effect is equipment- and protocol-specific. Read the evidence record →
Oral glutamine for treatment-related mucositis
Mixed evidence; formulation, treatment setting and route matter. Read the evidence record →
Swallowing exercises during radiotherapy
Adherence and functional endpoints require careful interpretation. Read the evidence record →
Safety and drug-interaction review: Mucositis, dehydration and swallowing difficulty need prompt clinical evaluation. Oral and intravenous glutamine have different risk profiles.
Clinical trials
- NCT05106608 — Photobiomodulation plus mobile-health support (LAXER). Head and neck cancer rehabilitation and symptoms. Registry status: recruiting; last update September 17, 2026.
- NCT03751566 — Acupuncture for acute radiotherapy toxicity. Head and neck cancer; registry status: recruiting; last update September 25, 2025.
Search additional trials: Search ClinicalTrials.gov for Head and neck cancer studies recruiting or not yet recruiting →. Results update at the registry; verify condition, intervention, eligibility and status on each study. Search links are not a vetted list of matching trials.
Pancreatic cancer
Treatment support and investigational cancer-control claims
Evidence categories: Supportive care · disease control · safety. The labels below are descriptive; they are not formal GRADE assessments.
IV vitamin C in pancreatic cancer
Investigational; do not infer benefit from laboratory or early trial endpoints. Read the evidence record →
Medicinal mushroom extracts
Evidence heterogeneous by extract and indication; not a substitute for systemic therapy. Read the evidence record →
Mistletoe extracts
Symptom or quality-of-life signals must not be equated with survival benefit. Read the evidence record →
Safety and drug-interaction review: Review renal function, G6PD status where relevant, infusion risks and interactions with cancer treatment before considering experimental infusions.
Clinical trials
- NCT07651358 — COMPASS — exercise and dietary support during neoadjuvant chemotherapy. Stage I–III pancreatic cancer; randomized feasibility-focused program. Registry status: recruiting; last update June 16, 2026.
- NCT06423963 — Remote exercise and nutrition prehabilitation. Pancreatic cancer before surgery. Last retrieved registry page showed recruitment, but its estimated completion was August 2026; current enrollment needs direct confirmation.
Search additional trials: Search ClinicalTrials.gov for Pancreatic cancer studies recruiting or not yet recruiting →. Results update at the registry; verify condition, intervention, eligibility and status on each study. Search links are not a vetted list of matching trials.
How to interpret the evidence
Benefit: positive, negative, mixed or insufficient human results for the stated clinical question. Certainty: judge sample size, bias, consistency and relevance; no formal rating is implied. Risk: adverse effects, interactions and treatment-specific cautions are separate from benefit. Trial status: registry descriptions do not establish efficacy or guarantee enrollment.
Additional cancer subtypes: browse by cancer. Other sources: NCI cancer clinical trials search resources · ClinicalTrials.gov · Safety & interactions.
Initial navigator published October 18, 2026. Curated evidence links; not an exhaustive or continuously synchronized trial database. See each linked record for its individual evidence review date.
